Product competition has sharpened between Eli Lilly & Co. and Novo Nordisk AS after the US Food and Drug Administration awarded the former’s blockbuster GLP-1 agonist Trulicity (dulaglutide) a cardiovascular (CV) label claim for diabetes patients with and without established heart disease. This makes it the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease.
Eli Lilly’s Trulicity’s Broad CV Label Spotlights GLP-1 Rivalry
Direct Impact On Novo Nordisk’s Ozempic ‘Limited’
Trulicity’s broad CV label awarded by the US FDA should aid overall uptake of the GLP-1 class, cushioning the direct impact on Novo Nordisk’s rival, Ozempic, analysts said.
More from Business
More from Scrip
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
In this week's episode: Merck & Co. licenses Hengrui’s lipid lowerer; Novo gets United’s triple G obesity drug; J&J plans major US manufacturing investments; approval for GSK’s novel antibiotic; and a call for more aggressive Korean M&A activity.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.